Picard Medical to Unveil Preclinical Emperor Heart Performance Data and Patient Outcomes
PMI•Picard Medical’s SynCardia team will present in vivo preclinical hemodynamic performance data for its next-generation Emperor Total Artificial Heart at ASAIO 2026 in New Orleans. Researchers will also disclose survival, recovery, transplantability and quality-of-life outcomes for patients supported by the SynCardia Total Artificial Heart.
1. Emperor Total Artificial Heart Preclinical Data
SynCardia researchers will report in vivo hemodynamic equivalence and circulatory support characteristics of the fully implantable, motor-driven Emperor Total Artificial Heart in large animal models on June 18 at ASAIO 2026.
2. Clinical Outcome Analysis for SynCardia Total Artificial Heart
On June 19, the team will present a comprehensive analysis of survival rates, recovery metrics, transplantability statistics and quality-of-life outcomes among patients supported by the SynCardia Total Artificial Heart.
3. Strategic Significance for Mechanical Circulatory Support
These presentations reinforce Picard Medical’s leadership in artificial heart technology, showcasing both established clinical success and progress toward a next-generation platform poised to expand treatment options for advanced biventricular heart failure.
